- Discovery
- Preclinical
- Phase 1
- Phase 2
PER-001 (Intravitreal Sustained Release Implant q6 months)
Open Angle Glaucoma
(IOP-independent therapy)
- Discovery
- Preclinical
- Phase 1
- Phase 2
Diabetic Retinopathy
- Discovery
- Preclinical
- Phase 1
- Phase 2
Dry AMD / Geographic Atrophy
- Discovery
- Preclinical
- Phase 1
- Phase 2
Retinal Vein Occlusion
- Discovery
- Preclinical
- Phase 1
- Phase 2
PER001 (topical)
Retinopathy of Prematurity
- Discovery
- Preclinical
- Phase 1
- Phase 2
Glaucoma
Glaucoma is a chronic, progressive disease characterized by damage to retinal ganglion cells and progressive vision loss. Current standard of care consists of pharmacological, laser or surgical therapies to reduce intraocular pressure (IOP), the only known modifiable risk factor for glaucoma. However, even with effective IOP lowering treatments, many patients continue to lose vision.
It is widely accepted that decreased ocular blood flow plays a role in glaucoma pathogenesis. Endothelin levels have been demonstrated to be elevated in patients with glaucoma. Endothelin is the most potent vasoconstrictor in the human body and blocking endothelin signaling increases ocular blood flow.
PER-001 Intravitreal Implant addresses a clear unmet medical need by preventing vision loss in glaucoma.
Diabetic retinopathy (DR)
Diabetic retinopathy (DR) is a complication of diabetes, associated with reduced blood flow in the retina (retinal non-perfusion, RNP). RNP leads to cell death as well as compensatory changes in the expression of a variety of signaling molecules, including vascular endothelial growth factor (VEGF). Increased VEGF levels lead to vascular leak and growth of abnormal new blood vessels resulting in damage to the retina. Current standard of care focuses on blocking VEGF and/or destroying peripheral retina via laser procedures to reduce VEGF production and oxygen consumption with hopes to preserve central retinal function. Current therapies do not address the underlying RNP, and many DR patients continue to lose vision.
Endothelin levels have been demonstrated to be elevated in DR patients. Endothelin is the most potent vasoconstrictor in the human body and blocking endothelin signaling increases ocular blood flow.
PER-001 Intravitreal Implant addresses a clear unmet medical need by preventing vision loss in patients with DR.
Please visit Clinicaltrials.gov to learn more about ongoing clinical trials.
